Antiphospholipid syndrome epidemiology and demographics: Difference between revisions

	Antiphospholipid syndrome Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Antiphospholipid syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic criteria
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Case Studies
Case #1
Antiphospholipid syndrome epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Antiphospholipid syndrome epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Antiphospholipid syndrome epidemiology and demographics
CDC on Antiphospholipid syndrome epidemiology and demographics
Antiphospholipid syndrome epidemiology and demographics in the news
Blogs on Antiphospholipid syndrome epidemiology and demographics
Directions to Hospitals Treating Antiphospholipid syndrome
Risk calculators and risk factors for Antiphospholipid syndrome epidemiology and demographics

Revision as of 01:13, 22 March 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

The incidence of antiphospholipid syndrome (APS) is approximately 5 cases per 100,000 persons per year.
In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

The prevalence of APS is approximately 40-50 cases per 100,000 persons worldwide.
In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
The case-fatality rate/mortality rate of [disease name] is approximately [number range].

There is no racial predilection to [disease name].
[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

[Disease name] affects men and women equally.
[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.

[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

@@ Line 20: / Line 20: @@
 ===Age===
-*Patients of all age groups may develop [disease name].
+*APS is more common in the elderly age group.
-*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
-*[Disease name] commonly affects individuals younger than/older than [number of years] years of age.
-*[Chronic disease name] is usually first diagnosed among [age group].
-*[Acute disease name] commonly affects [age group].
 ===Race===